How should kidney function be monitored during Tazemetostat therapy?

Serum creatinine, uric acid, phosphate and potassium early in responders (TLS surveillance); CBC per schedule (and surveillance for secondary malignancy); Volume status with GI toxicity.

How can kidney injury from Tazemetostat be prevented?

Tumor-lysis risk assessment with hydration +/- allopurinol or rasburicase in higher-risk lymphoma Maintain hydration; manage GI toxicity

Who is at higher risk of kidney injury from Tazemetostat?

High tumor burden/bulky lymphoma (tumor-lysis risk); Pre-existing CKD and concurrent nephrotoxins; Volume depletion from GI toxicity; Hyperuricemia at baseline.

Back to explorer

Printable monograph

EZH2 inhibitor

Tazemetostat

Tazverik · TAZ

EZH2 inhibitor · approved 2020 · 7 citations

Aging evidence· through 2022

Fairly sourced6/9 · 5 signals

Met: 7 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 12y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Not met: Current through 2022
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

First-in-class EZH2 inhibitor with a generally low direct renal toxicity — the kidney-relevant concern is treatment-related tumor lysis in lymphoma.

MildEpigenetic (EZH2) era

Relapsed/refractory follicular lymphoma (EZH2-mutant after >=2 prior therapies, or no satisfactory alternatives)Metastatic or unresectable epithelioid sarcoma not eligible for complete resection

§01

Signature kidney injury

Signature lesion

Prerenal / Hemodynamic AKI

Representative grade ≥3 incidence7%

Tazemetostat is generally well tolerated with low direct organ toxicity; the noted boxed risk is secondary T-cell lymphoma/myeloid malignancy. Tumor lysis is an uncommon, treatment-related concern in responding lymphoma. A discrete AKI rate is not quantified and direct nephrotoxicity is low. Reported rate: grade >=3 hyponatremia in 7% — 74 patients with relapsed or refractory malignant pleural mesothelioma (99% BAP1-inactivated) receiving single-agent… (Zauderer 2022, PMID 35588752).Source: Zauderer et al., Lancet Oncol 2022

Onset & rechallenge

Time to injuryAcute (~1–7 days)

Tumor lysis, if it occurs, is early after response; prerenal effects track GI toxicity.

Distilled from: “Tumor lysis, if it occurs, is early after response; prerenal effects track intercurrent GI toxicity.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Prerenal / Hemodynamic AKI#1 · Signaturequalitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Electrolyte DisturbanceSecondaryqualitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

7%grade ≥3 incidence

SeverityMild

ReversibilityReversible

Evidence7 citations

Nephron map

Vasculature / Endothelium

Distal Tubule / Collecting Duct

Tubular Lumen

Prerenal / Hemodynamic AKI

Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

Tazemetostat has no characteristic direct renal lesion. Its renal relevance is limited and indirect: in responding lymphoma, cytoreduction can release uric acid, phosphate and potassium, producing tumor-lysis crystalline nephropathy (urate and calcium-phosphate intratubular precipitation) and ATN; gastrointestinal toxicity and reduced intake can cause prerenal volume depletion. The epigenetic mechanism itself is not nephrotoxic.

Clinical presentation

Generally mild fatigue, nausea and musculoskeletal symptoms; when tumor lysis occurs, hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia and AKI early after a brisk response. Prerenal azotemia with poor intake.

Management

Treat tumor lysis with aggressive IV hydration, urate-lowering therapy (rasburicase for high uric acid), electrolyte correction and renal replacement if refractory. Restore volume for prerenal AKI. Given low intrinsic toxicity, routine dosing rarely needs renal-driven modification; renal events are generally reversible.Lesion-level management framework

Risk factors

High tumor burden/bulky lymphoma (tumor-lysis risk)
Pre-existing CKD and concurrent nephrotoxins
Volume depletion from GI toxicity
Hyperuricemia at baseline

Prevention

Tumor-lysis risk assessment with hydration +/- allopurinol or rasburicase in higher-risk lymphoma
Maintain hydration; manage GI toxicity

Anticancer mechanism· how it treats cancer

Oral selective inhibitor of EZH2, the catalytic subunit of polycomb repressive complex 2 (PRC2) that trimethylates histone H3 lysine 27 (H3K27me3). Inhibition reverses aberrant gene silencing in EZH2-mutant follicular lymphoma and in INI1/SMARCB1-deficient epithelioid sarcoma.

Note · The renal link is indirect and uncommon — chiefly treatment-related tumor lysis in responding lymphoma and prerenal volume depletion; direct nephrotoxicity is low. No taz-specific TLS/renal paper exists, so TLS/onconephrology consensus is cited.

§04

Clinical depth

Renal dose adjustment

No specific renal dose adjustment defined for mild-moderate impairment; severe impairment/ESKD not characterized (hepatic CYP3A metabolism). Modifications relate to hematologic toxicity and the secondary-malignancy risk.

Dialyzability & ESKD dosing

Highly protein-bound; not expected to be dialyzable. Dialysis is used for TLS metabolic complications, not drug removal.

Differential diagnosis

Distinguish tumor-lysis crystalline nephropathy (early hyperuricemia/hyperphosphatemia in responders) from prerenal azotemia and other AKI causes. The agent's low intrinsic toxicity makes a primary drug nephropathy unlikely.

Monitoring

Serum creatinine, uric acid, phosphate and potassium early in responders (TLS surveillance)
CBC per schedule (and surveillance for secondary malignancy)
Volume status with GI toxicity

Key trials & series

Morschhauser et al. (Lancet Oncol 2020) — registrational follicular lymphoma cohort
Gounder et al. (Lancet Oncol 2020) — epithelioid sarcoma cohort

Clinical pearls

Tazemetostat is generally well tolerated; the kidney-relevant concern is tumor lysis in responding lymphoma, not the drug itself.
Risk-stratify bulky lymphoma for TLS and pre-treat with hydration +/- rasburicase.
Remember the boxed secondary-malignancy risk when counseling and on long-term follow-up.
No tazemetostat-specific renal lesion is described.

§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 2010–2022 · 5 since 2020

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Apr 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

No dose adjustment of TAZVERIK is recommended for patients with mild to severe renal impairment or end stage renal disease [see Clinical Pharmacology ( 12.3 )] .

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 1,598 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 1 signal

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
Electrolyte DisturbanceNo disproportionate reporting — This phenotype IS reportable and this agent has enough reports, yet the reporting is not disproportionate — the one genuinely informative negative of the four.

Fanconi Syndrome

ROR 7.7095% CI 2.48–23.90· 3 reports

FAERS outcomes & reporting trend· 13.1% of reports w/ death · 20.2% w/ hospitalization

13.1%

Reported with a death outcome

209 of 1,598 reports

20.2%

Reported with hospitalization

322 of 1,598 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 9 systems · 1,598 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 0.2695% CI 0.08–0.80· 3 AKI reports ·AKI is reported less often than for other drugs (CI entirely below 1) — no disproportionate signal.

General / constitutional

Fatigue326Asthenia83Pain69Weight Decreased49Pyrexia45

Gastrointestinal

Nausea235Diarrhoea122Vomiting95Constipation80Abdominal Discomfort39

Nervous system

Headache74Taste Disorder52Dizziness50

Immune / infection

Covid-1972Pneumonia57

Respiratory

Cough65Dyspnoea57

Blood & lymphatic

Platelet Count Decreased53Anaemia49

Metabolic & electrolyte

Decreased Appetite97

Musculoskeletal

Arthralgia46Pain In Extremity40

Skin

Alopecia69

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Tazemetostat sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Olutasidenib

Rezlidhi · IDH1 inhibitor

Profile

Differentiation syndrome and tumor lysis in AML.

PRELYTE

Moderate#1 · 94% phenotype match

Tafasitamab

Monjuvi · Anti-CD19 antibody

Profile

Tumor lysis and infusion reactions in lymphoma.

PRELYTE

Mild#2 · 89% phenotype match

Mogamulizumab

Poteligeo · Anti-CCR4 antibody

Profile

Tumor lysis and rare AKI; cutaneous T-cell lymphoma.

PRELYTE

Mild#3 · 89% phenotype match

Midostaurin

Rydapt · FLT3 / multikinase inhibitor

Profile

Tumor lysis, edema and QT in AML/mastocytosis.

PRELYTE

Mild#4 · 89% phenotype match

Imetelstat

Rytelo · Telomerase inhibitor

Profile

2024 MDS agent; tumor lysis risk.

PRELYTE

Mild#5 · 88% phenotype match

Glasdegib

Daurismo · Hedgehog (SMO) inhibitor

Profile

QT prolongation and muscle spasms; AML.

PRELYTE

Mild#6 · 85% phenotype match

Compare Tazemetostat with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Other targeted agents

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.